title: Pharmacology in space: pharmacotherapy.
abstract: This chapter summarized the information available on the pharmacological kits onboard spacecraft and on the use of drugs in space, while the next chapter is dedicated to the impacts of weightlessness on drug pharmacokinetics. The need of a selected group of drugs for the use of astronauts during short-term and long-term spaceflights has been discussed. Recommendations are made for a Space Pharmacopoeia as well as for the areas of research needed to adapt medication to the weightlessness of the space environment. Although the usefulness of these drugs has been clearly demonstrated, their use also raises several problems. Physiological changes due to weightlessness may induce changes in pharmacokinetic behavior of drugs and influence their dosage regimen. Inflight data obtained by salivary drug monitoring have shown changes in the distribution of scopolamine and a significant change in the disposition of the common pain-relief agent acetaminophen taken inflight, in both drug concentration and time course. The authors of this study emphasize, however, that their data are preliminary and as yet incomplete. Further simulation studies and, if possible, inflight experiments are required. In vitro studies of the antibacterial activity of antibiotics under space conditions have shown an increased resistance of Escherichia Coli to colistin and kanamycin, and a lowered resistance of Staphylococcus Aureus to oxacillin, chloramphenicol, and erythromycin. The possible consequences of these findings for the treatment of infections contracted by astronauts are yet to be elucidated. There is still a lack of pharmacological countermeasures, particularly for preventing the progressive bone demineralization occurring in weightlessness. The treatment of space motion sickness with drugs carries with it the problem of undesirable side-effects on psychomotor performance. In order to arrive at the most appropriate medical kit for a particular mission, the best trade-off of risk versus benefit for the individual and the mission must always be attempted for any pharmacological agent.
authors.affiliation: Institut de Medecine et de Physiologie Spatiales Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Pavy-Le Traon
authors.forename: S
authors.initials: S
authors.lastname: Saivin
authors.forename: C
authors.initials: C
authors.lastname: Soulez-LaRivière
authors.forename: M
authors.initials: M
authors.lastname: Pujos
authors.forename: A
authors.initials: A
authors.lastname: Güell
authors.forename: G
authors.initials: G
authors.lastname: Houin
mesh_terms: D000337:Aerospace Medicine; D004358:Drug Therapy / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D005392:First Aid / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D010600:Pharmacology; D012426:Russia; D013026:Space Flight; D014481:United States